Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Financing Activities: 2011-2025

Historic Cash from Financing Activities for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $148,000.

  • Niagen Bioscience's Cash from Financing Activities fell 85.76% to $148,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 595.40%. This contributed to the annual value of $5.4 million for FY2024, which is 6065.56% up from last year.
  • As of Q3 2025, Niagen Bioscience's Cash from Financing Activities stood at $148,000, which was down 96.05% from $3.7 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Cash from Financing Activities high stood at $33.4 million for Q1 2021, and its period low was -$76,000 during Q4 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $148,000 (2025), whereas its average is $1.1 million.
  • In the last 5 years, Niagen Bioscience's Cash from Financing Activities spiked by 90,291.89% in 2021 and then plummeted by 1,300.00% in 2024.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Cash from Financing Activities stood at $63,000 in 2021, then skyrocketed by 12,088.89% to $7.7 million in 2022, then crashed by 100.99% to -$76,000 in 2023, then skyrocketed by 5,031.58% to $3.7 million in 2024, then slumped by 85.76% to $148,000 in 2025.
  • Its Cash from Financing Activities stands at $148,000 for Q3 2025, versus $3.7 million for Q2 2025 and $3.1 million for Q1 2025.